Skip to main content
. 2017 Dec 29;10:29–43. doi: 10.2147/CEOR.S148195

Table 1.

Estimates of effectiveness of treatment (IPSS improvements), durability of effects, and transition probabilitiesa for occurrence of early and late AEs

Number of subjects included in effectiveness and safety assessments
Change in IPSS compared with baseline*
Return of LUTS (% patients)
Baseline Year 1 Year 2 Year 1 Year 2 Reference Per 6-month cycle Reference
ComboRx 2,524 2,403 1,575 ComboRx −1.70 −6.20 22,23 0.70 23
Rezūm® 189 165 109 Rezūm −11.65 −11.80 24–26 0.60 24–26
UroLift® 420 331 136 UroLift −10.65 −9.47 27–33 4.92 27–29
Prostiva® 626 346 139 Prostiva −11.24 −11.06 34–40 0.93 34,37,38,41
Greenlight® PVP 2,478 1,185 432 Greenlight PVP −15.08 −13.62 42–50 0.93 42–46,48,49,51–54
TURP 539 429 302 TURP −16.79 −13.06 33,35,36,44–46,49,54–58 0.31 44–46,49,58
AEs (% patients) per 6-month cycle
Incontinence De novo erectile dysfunction Stricture, contracture, or stenosis Acute urinary retention Urinary tract infection
Therapy Earlyb Latec Ref. Early Ref. Early Late Ref. Through Year 2 Ref. Early Late Ref.
ComboRx 0.07 0.02 22 5.38 59 0.01d 0.01d NA 0.07 22 0.07 0.02 22
Rezūm 0.01d 0.01d 24–26 0.01d 24–26 1.13 0.42 24–26 0.27 24–26 1.99 0.43 24–26
UroLift 1.05 0.97 27–33 0.01d 27–33 0.01d 0.01d 33 1.31 26–33 2.17 0.64 27–33
Prostiva 0.01d 0.26 39 0.46 36,39 0.01d 0.11 36–39 0.01d NA 4.77 1.59 39
Greenlight PVP 4.75 0.01d 42,43,45,46,52 0.01d 43,45,46,60 1.51 0.61 43–51,53,54 1.30 43,50,51, 53,54 19.90e 1.11 44,46,50, 51,53,54
TURP 2.06 0.78 50,51,54,58,61 1.05 33,46 4.66 0.62 46,49–51,54,58,61 1.76 33,50, 51,54 12.23e 2.09 33,46,50, 51,54,61

Notes:

A decrease (minus sign) in IPSS represents an improvement compared with baseline. A common baseline IPSS of 22 was used for comparison of the treatment modalities in the model. For the modeling, it is assumed that ComboRx is the typical first line of treatment for LUTS/BPH. Patients who have inadequate symptom relief or worsening of LUTS may progress to one of the three MIT options (0.33 assumption). Patients who progress after an MIT have two surgical options (0.5 assumption). Early AEs are those occurring within 6 months after treatment, while late AEs are those occurring 6 months or later after treatment.

a

Per 6-month cycle.

b

First 6-month cycle.

c

After first 6-month cycle.

d

When AE is not reported in any source, the rate is indicated as 0.01 for modeling purposes.

e

Early rates in the few papers with reports were very high.

*

From baseline reported in the individual papers.

Abbreviations: AE, adverse event; BPH, benign prostatic hyperplasia; ComboRx, combination prescription drug therapy; Greenlight PVP, photovaporization of the prostate; IPSS, International Prostate Symptom Score; LUTS, lower urinary tract symptoms; MIT, minimally invasive therapy; NA, not available; Prostiva, conductive radiofrequency thermal therapy; Ref., reference; Rezūm, convective radiofrequency water vapor thermal therapy; TURP, transurethral resection of the prostate; UroLift, prostatic urethral lift.